天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Recent Results in Cancer Research >>article

Recent Results in Cancer Research

Download PDF

Axitinib (AG-013736).

Published:1 January 2010 DOI: 10.1007/978-3-642-01222-8_3 PMID: 20072829
Ronan Joseph Kelly, Olivier Rixe

Abstract

The vascular endothelial growth factor (VEGF)/VEGF receptor tyrosine kinase (RTK) signaling pathway plays a pivotal role in tumor angiogenesis. Neovascularization promotes increased tumor cell proliferation, survival and metasasis. Many antiangiogenic agents including multi-RTK inhibitors are either approved or are undergoing testing in clinical trials. Axitinib is a potent and selective inhibitor of VEGF RTK 1, 2, and 3. This chapter discusses the stucture of axitinib as well as its toxicities and drug interactions. Important preclinical and clinical data for axitinib are presented including findings from phase II studies in many tumor types including malignant melanoma and renal, pancreatic, thyroid, breast, lung and colorectal carcinomas. Ongoing phase III studies in pancreatic and metastatic renal cell carcinoma will ultimately define the therapeutic role of this targeted agent.

Substances (4)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Axitinib 319460-85-0 C22H18N4OS 473 suppliers $39.00-$1154.00
HUMAN VEGF165 127464-60-2 NULL 133 suppliers $98.40-$908.00
VEGF Receptor 2 9 suppliers Inquiry
RTK TOTAL 7-PLEX 4 suppliers Inquiry

Similar articles

IF:4.6

Clinical pharmacology of axitinib.

Clinical Pharmacokinetics Ying Chen, Michael A Tortorici,etc Published: 1 September 2013